Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model
Open accessThe DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
The 2015 European pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH). Low-, intermediate- and high-risk strata are defined by estimated 1-year mortality risks of <5%, 5–10% and >10%, respectively. This risk assessment strategy awaits validation. We analysed data from patients with newly diagnosed PAH enrolled into COMPERA (Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension), a European-based PH registry. An abbreviated version of the risk assessment strategy proposed by the European PH guidelines was applied, using the following variables: World Health Organization functional class, 6-min walking distance, brain natriuretic peptide or its N-terminal fragment, right atrial pressure, cardiac index and mixed venous oxygen saturation. Data from 1588 patients were analysed. Mortality rates were significantly different between the three risk strata (p<0.001 for all comparisons). In the entire patient population, the observed mortality rates 1 year after diagnosis were 2.8% in the low-risk cohort (n=196), 9.9% in the intermediate-risk cohort (n=1116) and 21.2% in the high-risk cohort (n=276). In addition, the risk assessment strategy proved valid at follow-up and in major PAH subgroups. An abbreviated version of the risk assessment strategy proposed by the current European PH guidelines provides accurate mortality estimates in patients with PAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several European registries have since validated the ESC/ERS risk status model; however, it is unknown if the ESC/ERS tool predicts clinical worsening or hospitalizations.(288)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [288]
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationAuthors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
Self-citationMacitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H.-A., Jansa, P., Jing, Z.-C., Le Brun, F.-O., Mehta, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213917 · Cited by 1,443
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A. E., Ghofrani, H.-A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J.-L., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationSelexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Self-citationBenza, R. L., Gomberg-Maitland, M., Miller, D. P., Frost, A., Frantz, R. P., Foreman, A. J., Badesch, D. B., & McGoon, M. D. (2012) · Chest · doi:10.1378/chest.11-0676 · Cited by 557
Kylhammar, D., Kjellström, B., Hjalmarsson, C., Jansson, K., Nisell, M., Söderberg, S., Wikström, G., & Rådegran, G. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx257 · Cited by 540
Hoeper, M. M., Huscher, D., Ghofrani, H. A., Delcroix, M., Distler, O., Schweiger, C., Grunig, E., Staehler, G., Rosenkranz, S., Halank, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.10.026 · Cited by 466
Self-citationUpfront triple combination therapy in pulmonary arterial hypertension: a pilot study
Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., Bouvaist, H., Dauphin, C., Picard, F., Bulifon, S., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00116313 · Cited by 382
Cited by
Items 101–200 of 739
Mercurio, V., Diab, N., Peloquin, G. L., Housten-Harris, T., Damico, R. L., Kolb, T. M., Mathai, S. C., & Hassoun, P. M. (2018) · European Respiratory Journal · doi:10.1183/13993003.00497-2018 · Cited by 47
Badagliacca, R., Papa, S., Poscia, R., Valli, G., Pezzuto, B., Manzi, G., Torre, R., Gianfrilli, D., Sciomer, S., Palange, P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.11.015 · Cited by 46
Self-citationManagement of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
Almaaitah, S., Highland, K. B., & Tonelli, A. R. (2020) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s232038 · Cited by 46
Treatment of right ventricular dysfunction and heart failure in pulmonary arterial hypertension
Inampudi, C., Tedford, R. J., Hemnes, A. R., Hansmann, G., Bogaard, H. J., Köestenberger, M., Lang, I. M., & Brittain, E. L. (2020) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-348 · Cited by 45
D’Alto, M., Badagliacca, R., Giudice, F. L., Argiento, P., Casu, G., Corda, M., Correale, M., Ghio, S., Greco, A., Lattanzio, M., et al. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.08.016 · Cited by 44
Self-citationRosenkranz, S., Feldman, J., McLaughlin, V. V., Rischard, F. P., Lange, T. J., White, R. J., Peacock, A. J., Gerhardt, F., Ebrahimi, R., Brooks, G. C., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00032-1 · Cited by 44
Self-citation2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension
Huang, W., Hsu, C., Sung, S., Ho, W., Chu, C., Chang, C.-P., Chiu, Y., Wu, C., Chang, W., Lin, L., et al. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.12.009 · Cited by 43
Vicenzi, M., Caravita, S., Rota, I., Casella, R., Deboeck, G., Beretta, L., Lombi, A., & Vachiéry, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265059 · Cited by 43
“Patients were classified according to three risk assessment methods: 1) COMPERA registry strategy, 2) invasive, and 3) non-invasive method of FPHN registry [6,7].”
BackgroundMethodRisk assessment in pulmonary arterial hypertension
Boucly, A., Weatherald, J. C., Humbert, M. J. C., & Sitbon, O. (2018) · European Respiratory Journal · doi:10.1183/13993003.00279-2018 · Cited by 42
Cirulis, M. M., Ryan, J. J., & Archer, S. L. (2019) · Pulmonary Circulation · doi:10.1177/2045894019834890 · Cited by 41
Anderson, J., Lau, E., Lavender, M. A., Benza, R. L., Celermajer, D. S., Collins, N. J., Corrigan, C., Dwyer, N., Feenstra, J., Horrigan, M., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.2203 · Cited by 41
Kojima, H., Tokunou, T., Takahara, Y., Sunagawa, K., Hirooka, Y., Ichiki, T., & Tsutsui, H. (2019) · Physiological Reports · doi:10.14814/phy2.14025 · Cited by 40
“In COMPERA registry, 5-year mortality of pulmonary arterial hypertension is range from 24% (low-risk group) to 68% (high-risk group) (Hoeper et al. 2017).”
Backgroundvan der Bruggen, C. E. E., Handoko, M. L., Bogaard, H. J., Marcus, J. T., Oosterveer, F. P. T., Meijboom, L. J., Westerhof, B. E., Noordegraaf, A. V., & de Man, F. S. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.10.077 · Cited by 40
“This limited the possibilities to perform multivariate regression analyses including general prognostic markers of PAH.”
BackgroundInfluentialRiociguat: Clinical research and evolving role in therapy
Klinger, J. R., Chakinala, M. M., Langleben, D., Rosenkranz, S., & Sitbon, O. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14676 · Cited by 40
Self-citationA novel secreted-cAMP pathway inhibits pulmonary hypertension via a feed-forward mechanism
Jones, C. R., Bisserier, M., Bueno‐Betí, C., Bonnet, G., Neves, S. R., Lee, S.-Y., Milara, J., Dorfmüller, P., Humbert, M. J. C., Leopold, J. A., et al. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz244 · Cited by 39
“Pulmonary arterial hypertension (PAH), a rare disease with an estimated prevalence of 15–50 per million populations,(1) is usually progressive, leading to right heart failure and ultimately death.(2,3) Despite advances in clinical management of PAH, there is no cure for PAH, highlighting the need for new directions an…”
BackgroundDatabase of Pulmonary Hypertension in the Polish Population (BNP‑PL): design of the registry
Kopeć, G., Kurzyna, M., Mroczek, E., Chrzanowski, Ł., Mularek‐Kubzdela, T., Skoczylas, I., Kuśmierczyk, B., Pruszczyk, P., Błaszczak, P., Lewicka, E., et al. (2019) · Kardiologia Polska · doi:10.33963/kp.14988 · Cited by 39
Kramer, T., Wißmüller, M., Natsina, K., Gerhardt, F., ten Freyhaus, H., Dumitrescu, D., Viethen, T., Hellmich, M., Baldus, S. E., & Rosenkranz, S. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12764 · Cited by 39
“The mean grade was rounded off to the nearest integer, which was used to define the patient’s risk group.(27,28) (ii) Identification of ‘low-risk status’ using the non-invasive three-criteria approach by”
MethodSelf-citationHoeper, M. M., Pausch, C., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H. J., Distler, O., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.03.011 · Cited by 39
Self-citationAcquired disorders of mitochondrial metabolism and dynamics in pulmonary arterial hypertension
Breault, N. M., Wu, D., Dasgupta, A., Chen, K., & Archer, S. L. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1105565 · Cited by 39
“Current PHtargeted drugs, alone or in combination, are therefore not curative and annual mortality rates in PAH patient populations remain above 10%, suggesting that new therapeutic targets are needed (Hoeper et al., 2017).”
BackgroundBlette, B. S., Moutchia, J., Al‐Naamani, N., Ventetuolo, C. E., Cheng, C., Appleby, D. H., Urbanowicz, R. J., Fritz, J. S., Mazurek, J. A., Li, F., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00155-8 · Cited by 39
Beyond Thrombosis: the Role of Platelets in Pulmonary Hypertension
Nicoleau, S., & Wójciak‐Stothard, B. (2020) · SciMedicine Journal · doi:10.28991/scimedj-2020-0204-7 · Cited by 38
Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)
Chazova, I. E., Martynyuk, T. V., Shmalts, A. A., Владимирович, Г. В., Danilov, N. M., Veselova, T. N., Захаровна, К. И., Шогаибович, С. А., Стукалова, О. В., Азизов, В. А., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-1-6-85 · Cited by 38
Reinders, S., Didden, E., & Ong, R. C.-Y. (2024) · Respiratory Research · doi:10.1186/s12931-024-02994-w · Cited by 38
“…models have been developed since the recommendation by the ESC/ERS, including those based on the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) [18, 19], and the Registry to Evaluate Early and Long-term PAH disease management (REVEAL) [20].”
MethodRichter, M. J., Harutyunova, S., Bollmann, T., Claßen, S., Gall, H. J., Gerhardt, F., Grimminger, F., Grimminger, J., Grünig, E., Guth, S., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.06.006 · Cited by 38
Self-citationIntravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension
Olsson, K. M., Richter, M. J., Kamp, J. C., Gall, H. J., Heine, A., Ghofrani, H. A., Fuge, J., Ewert, R., & Hoeper, M. M. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.05.002 · Cited by 38
Self-citationArvanitaki, A., Boutsikou, M., Anthi, A., Apostolopoulou, S. C., Avgeropoulou, A., Demerouti, E., Farmakis, D. T., Feloukidis, C., Giannakoulas, G. A., Karvounis, H. I., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019877157 · Cited by 38
“WHO FC, 6-MWD, NT-proBNP, right atrial pressure (RAP), cardiac index (CI), and mixed venous oxygen saturation at baseline were used for the risk stratification, if available.(16) The cut-off values proposed in the European guidelines(1) were graded 1–3 (1: low risk, 2: intermediate risk, and 3: high risk).”
MethodResultInfluentialMinopoulou, I., Theodorakopoulou, M. P., Boutou, A., Arvanitaki, A., Pitsiou, G., Doumas, M. N., Sarafidis, P. A., & Dimitroulas, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071528 · Cited by 38
“According to recent studies from European PAH registries, the percentage of SSc-PAH presenting with New York Heart Association (NYHA) functional class III or IV symptoms at the time of diagnosis reaches 75% [51,52], and remains approximately as high as 30 years ago [53].”
BackgroundBredfelt, A., Rådegran, G., Hesselstrand, R., Arheden, H., & Ostenfeld, E. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12304 · Cited by 37
Vanderpool, R. R., Hunter, K. S., Insel, M. B., Garcia, J. G. N., Bedrick, E. J., Tedford, R. J., & Rischard, F. P. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.09.040 · Cited by 37
Vanderpool, R. R., Puri, R., Osorio, A., Wickstrom, K., Desai, A. A., Black, S. M., Garcia, J. G. N., Yuan, J. X. ‐., & Rischard, F. P. (2019) · Pulmonary Circulation · doi:10.1177/2045894019850993 · Cited by 36
“While a right heart catheterization (RHC) remains the standard for diagnosing PH, risk stratification strategies for assessing prognosis in PH demonstrate that functional measurements like 6-min walking distance (6MWD), World Health Organization (WHO) functional class (FC), brain natriuretic peptide, and clinical wors…”
BackgroundPulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment
Attanasio, U., Cuomo, A., Pirozzi, F., Loffredo, S., Abete, P., Petretta, M., Marone, G., Bonaduce, D., de Paulis, A., Rossi, F. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124430 · Cited by 36
“When these risk prediction models were applied to a 151-strong SSc–PAH patient population, whether using the “French” (FPHN) method or the “European” (SPAHR and COMPERA) approach, the results confirmed the accuracy of the guideline risk table in predicting patients’ survival.”
MethodInfluentialHighland, K. B., Crawford, R., Classi, P. M., Morrison, R., Doward, L. C., Nelsen, A. C., Castillo, H., Mathai, S. C., & DuBrock, H. M. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01782-0 · Cited by 36
Kjellström, B., Nisell, M., Kylhammar, D., Bartfay, S.-E., Ivarsson, B., Rådegran, G., & Hjalmarsson, C. (2019) · ERJ Open Research · doi:10.1183/23120541.50075-2019 · Cited by 36
Inpatient Palliative Care Use in Patients With Pulmonary Arterial Hypertension
Anand, V., Vallabhajosyula, S., Cheungpasitporn, W., Frantz, R. P., Cajigas, H. R., Strand, J. J., & DuBrock, H. M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.079 · Cited by 35
Portopulmonary Hypertension: Prevalence, Clinical and Hemodynamic Features
Navarro-Vergara, D.-I., Roldán-Valadéz, E., Cueto‐Robledo, G., & Jurado-Hernandez, M. Y. (2020) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2020.100747 · Cited by 36
The prognostic value of DLCO and pulmonary blood flow in patients with pulmonary hypertension
Stadler, S., Mergenthaler, N., & Lange, T. J. (2019) · Pulmonary Circulation · doi:10.1177/2045894019894531 · Cited by 34
“Different parameters have been used separately or in combination to predict the prognosis of PH patients.(2,4) Clinical parameters like the World Health Organization Functional Class (WHO-FC) can predict survival both at diagnosis and follow-up (on specific treatment).”
BackgroundMethodAdvanced imaging in pulmonary hypertension: emerging techniques and applications
Rengier, F., Melzig, C., Derlin, T., Marra, A. M., & Vogel‐Claussen, J. (2018) · International journal of cardiac imaging · doi:10.1007/s10554-018-1448-4 · Cited by 34
Hjalmarsson, C., Kjellström, B., Jansson, K., Nisell, M., Kylhammar, D., Kavianipour, M., Rådegran, G., Söderberg, S., Wikström, G., Wuttge, D. M., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00854-2020 · Cited by 34
Kanwar, M. K., Raina, A., Lohmueller, L. C., Kraisangka, J., & Benza, R. L. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0950-y · Cited by 33
Lewis, R. A., Billings, C., Hurdman, J. A., Smith, I. A., Austin, M., Armstrong, I. J., Middleton, J. T., Rothman, A. M. K., Harrington, J., Hamilton, N., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-423oc · Cited by 33
“As has been demonstrated with other prognostic investigations and risk stratification tools, patients who improved their risk profile demonstrated comparable longer-term survival to patients originally displaying that level of risk (24, 34, 35).”
ResultRisk assessment in pulmonary hypertension based on routinely measured laboratory parameters
Yogeswaran, A., Tello, K., Lund, J., Klose, H. F. E., Harbaum, L., Sommer, N., Oqueka, T., Hennigs, J. K., Grimminger, F., Seeger, W., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.018 · Cited by 33
Self-citationBadagliacca, R., Rischard, F. P., Giudice, F. L., Howard, L., Papa, S., Valli, G., Manzi, G., Sciomer, S., Palange, P., Garcia, J. G. N., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.02.021 · Cited by 32
Self-citationMortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids
Bartolome, S., Sood, N., Shah, T. G., Styrvoky, K. C., Torres, F., & Chin, K. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.03.050 · Cited by 32
“registry.(4,6) However, only a small number of patients receiving prostanoids (parenteral or otherwise) were included in these studies, and outcomes according to ESC/ERS risk criteria for this patient population have not been reported.”
ResultTyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices
Rieg, A. D., Bünting, N. A., Cranen, C., Suleiman, S., Spillner, J. W., Schnöring, H., Schröder, T., von Stillfried, S. F., Braunschweig, T. A., Manley, P. W., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1074-2 · Cited by 32
Nuche, J., de la Cal, T. S., López-Guarch, C. J., López‐Medrano, F., Delgado, C. P.-O., Arribas, F., Delgado, J. F., Ibáñez, B., Oliver, E., & Subías, P. E. (2020) · Diagnostics · doi:10.3390/diagnostics10080548 · Cited by 31
“The resultant increased pulmonary arterial pressures in PAH and CTEPH contribute to a further increase of the right ventricular afterload, thus leading to right ventricular dysfunction and reducing survival among affected patients, being heart failure the most common cause of death [10].”
BackgroundBrown, Z., Proudman, S., Morrisroe, K., Stevens, W., Hansen, D., & Nikpour, M. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.03.011 · Cited by 31
Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials
Ventetuolo, C. E., Moutchia, J., Baird, G. L., Appleby, D. H., McClelland, R. L., Minhas, J., Min, J., Holmes, J. H., Urbanowicz, R. J., Al‐Naamani, N., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202203-207oc · Cited by 31
Kocken, J. M. M., & Martins, P. A. D. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238901 · Cited by 31
“Whereas survival rates of patients are much dependent on the etiology of PAH and symptom severity, on average, a five-year survival rate between 40–60% is observed [22,23].”
BackgroundAssessing risk in pulmonary arterial hypertension: what we know, what we don't
Benza, R. L., Farber, H. W., Selej, M., & Gomberg‐Maitland, M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01353-2017 · Cited by 31
Khirfan, G., Almoushref, A., Naal, T., AbuHalimeh, B. J., Dweik, R. A., Heresi, G. A., & Tonelli, A. R. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.06.053 · Cited by 30
“< 165 6 (10) NT-pro BNP, pg/mL (n 1⁄4 136)”
Benza, R. L., Gomberg‐Maitland, M., Farber, H. W., Vizza, C. D., Broderick, M. J., Holdstock, L., Nelsen, A. C., Deng, C., Rao, Y., & White, R. J. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.08.006 · Cited by 30
Self-citationMagnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats
Chang, C., Shih, H., Huang, I., Tsai, P., Chen, K.-Y., & Huang, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184622 · Cited by 30
“However, these medications do not improve clinical outcomes [5].”
BackgroundMcLaughlin, V. V., Sitbon, O., Chin, K., Galiè, N., Hoeper, M. M., Kiely, D. G., MacDonald, G., Martin, N., Mathai, S. C., Peacock, A. J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3319 · Cited by 29
Self-citationRisk stratification in chronic thromboembolic pulmonary hypertension predicts survival
Sandqvist, A., Kylhammar, D., Bartfay, S.-E., Hesselstrand, R., Hjalmarsson, C., Kavianipour, M., Nisell, M., Rådegran, G., Wikström, G., Kjellström, B., et al. (2020) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2020.1783456 · Cited by 29
“have suggested that risk assessment could be considered as an end-point in future clinical trials [16,17], which we fully endorse also in studies involving CTEPH patients.”
BackgroundAdvanced risk stratification of intermediate risk group in pulmonary arterial hypertension
Yogeswaran, A., Richter, M. J., Sommer, N., Ghofrani, H. A., Seeger, W., Tello, K., & Gall, H. J. (2020) · Pulmonary Circulation · doi:10.1177/2045894020961739 · Cited by 29
“We chose 6MWD as the main parameter for our advanced stratification because it was previously shown to be one of the main predictors of mortality in the ESC/ERS risk score.(3) Of note, 6MWD was sufficient for stratification only after imputation of missing data, whereas 6MWD combined with TAPSE/PASP was able to strati…”
BackgroundMethodResultSelf-citationSahay, S., Tonelli, A. R., Selej, M., Watson, Z., & Benza, R. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241504 · Cited by 29
“Patient risk was then calculated independently using COM- PERA, FPHR and REVEAL 2.0 tools.”
MethodResultInfluentialBenza, R. L., Ghofrani, H. A., Grünig, E., Hoeper, M. M., Jansa, P., Jing, Z., Kim, N. H., Langleben, D., Simonneau, G., Wang, C., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.06.020 · Cited by 29
Self-citationHo, L., Hossen, M. N., Nguyen, T. B., Vo, A., & Ahsan, F. (2022) · Biomedicines · doi:10.3390/biomedicines10010170 · Cited by 29
Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension
de Miguel, I. M., Cruz‐Utrilla, A., Oliver, E., & Subías, P. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044147 · Cited by 29
Natural history of chronic thromboembolic pulmonary disease with no or mild pulmonary hypertension
Reddy, S. A., Świetlik, E. M., Robertson, L., Michael, A., Boyle, S., Polwarth, G. J., Screaton, N., Ruggiero, A., Nethercott, S. L., Taboada, D., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.04.016 · Cited by 29
Xanthouli, P., Kögler, M., Marra, A. M., Benjamin, N., Fischer, L., Eichstaedt, C. A., Harutyunova, S., Nagel, C., Grünig, E., & Egenlauf, B. (2020) · Respiratory Research · doi:10.1186/s12931-020-01393-1 · Cited by 29
Self-citationEnrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials
Scott, J. V., Garnett, C. E., Kanwar, M. K., Stockbridge, N., & Benza, R. L. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0357oc · Cited by 29
“Further investigations are warranted to explore whether REVEAL Lite (22) or the French noninvasive score (6) can identify the intermediate–high and/or high-risk–only groups with considerably fewer variables and no hemodynamic variables.”
BackgroundMethodResultFarmakis, I. T., Demerouti, E., Karyofyllis, P., Karatasakis, G., Stratinaki, M., Tsiapras, D. P., Athanassopoulos, G. D., Voudris, V. V., & Giannakoulas, G. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132826 · Cited by 29
Hickey, P. M., Lawrie, A., & Condliffe, R. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00175 · Cited by 28
Andrographolide Attenuates Established Pulmonary Hypertension via Rescue of Vascular Remodeling
Nie, X., Shen, C., Tan, J., Yang, X., Wang, W., Dai, Y., Sun, H., Wu, Z., & Chen, J. (2021) · Biomolecules · doi:10.3390/biom11121801 · Cited by 27
“Mor over, t ey only have a limited impact on mortality [23].”
Backgrounddel Castillo, A. G., López‐Meseguer, M., Fonollosa‐Pla, V., Sáez, B., Colunga-Argüelles, D., Revilla‐López, E., Rubio‐Rivas, M., Ropero, M. J. C., Argibay, A. B., Barberà, J. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09353-z · Cited by 27
Åberg, M., Björklund, E., Wikström, G., & Christersson, C. (2022) · Platelets · doi:10.1080/09537104.2022.2087867 · Cited by 27
“Despite the development of advanced therapies, survival prospects remain poor for both conditions with right ventricular failure as the main cause of early death [6].”
Coursen, J. C., Simpson, C. E., Mukherjee, M., Vaught, A. “. J., Kutty, S., Al‐Talib, T. K., Wood, M. J., Scott, N. S., Mathai, S. C., & Sharma, G. V. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9080260 · Cited by 27
“• Modified WHO Classification • Class IV: Extremely High–Risk Maternal Mortality and Morbidity (cardiomyop thy with LVEF 30%, pulmonary hypertension, native severe coarctation, severe mitral and aortic stenosis) = 40–100% risk of maternal cardiovascular complications • CARPREG II Risk Predictors (Weighted risk score b…”
BackgroundInfluentialBlood carbon dioxide tension and risk in pulmonary arterial hypertension
Harbaum, L., Fuge, J., Kamp, J. C., Hennigs, J. K., Simon, M., Sinning, C., Oqueka, T., Grimminger, J., Olsson, K. M., Hoeper, M. M., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.06.069 · Cited by 27
Self-citationGonzález‐Candia, A., Arias, P. V., Aguilar, S. A., Figueroa, E. G., Reyes, R. V., Ebensperger, G., Llanos, A. J., & Herrera, E. A. (2021) · Antioxidants · doi:10.3390/antiox10111658 · Cited by 27
“However, if pressure overload remains (as seen in PAHN) the adaptive response gradually shifts to a maladaptive remodeling towards RV failure [8].”
BackgroundOutcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit
Garcia, M. V. F., Souza, R., Costa, E. L. V., Fernandes, C. J. C. D. S., Jardim, C., & Caruso, P. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106685 · Cited by 27
The economic burden of pulmonary arterial hypertension in Spain
Zozaya, N., Abdalla, F., Moreno, I., Crespo-Diz, C., Gallardo, A. M. R., Soriano, J. R., Galán, M. A., & Hidalgo‐Vega, Á. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01906-2 · Cited by 26
Outcomes and risk assessment in pulmonary veno-occlusive disease
Boucly, A., Solinas, S., Beurnier, A., Jaïs, X., Keddache, S., Eyries, M., Seferian, A., Jevnikar, M., Roche, A., Bulifon, S., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00612-2023 · Cited by 26
Risk stratification in pulmonary arterial hypertension
Weatherald, J. C., Boucly, A., & Sitbon, O. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000510 · Cited by 26
Stolfo, D., Albani, S., Biondi, F., Luca, A. D., Barbati, G., Howard, L., Giudice, F. L., Tsampasian, V., Pasanisi, E. M., Airò, E., et al. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.05.020 · Cited by 26
Sitbon, O., Nikkho, S. M., Benza, R. L., Deng, C. Q., Farber, H. W., Gomberg‐Maitland, M., Hassoun, P. M., Meier, C., Pepke‐Żaba, J., Prasad, K., et al. (2020) · Pulmonary Circulation · doi:10.1177/2045894020962960 · Cited by 26
“(8)Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.(35) (9)The REVEAL Risk Score Calculator 2.”
BackgroundHoeper, M. M., Sanchez, M.-A. G., Humbert, M. J. C., Pittrow, D., Simonneau, G., Gall, H. J., Grünig, E., Klose, H. F. E., Halank, M., Langleben, D., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106241 · Cited by 26
“The association of EXPERT with COMPERA, in which patients are older than in other registries [23], may have encouraged the enrollment of older patients.”
MethodSelf-citationKim, N. H., Hemnes, A. R., Chakinala, M. M., Highland, K. B., Chin, K., McLaughlin, V. V., Zhao, C., NARAYAN, V., & Farber, H. W. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.01.006 · Cited by 26
Novel Treatment Pathways in Pulmonary Arterial Hypertension
Qaiser, K. N., & Tonelli, A. R. (2021) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/cbhs2234 · Cited by 26
Alves-Silva, J. M., Zuzarte, M., Marques, C., Viana, S., Preguiça, I., Baptista, R., Ferreira, C., Cavaleiro, C., Domingues, N. S., Sardão, V. A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2022.106151 · Cited by 25
Simons, J. E., Mann, E. B., & Pierozynski, A. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01030-4 · Cited by 25
Sahay, S., Bhatt, J., Beshay, S. M., Guha, A., Nguyen, D. T., Graviss, E. A., & Nagueh, S. F. (2021) · Pulmonary Circulation · doi:10.1002/pul2.12026 · Cited by 24
Michalski, T. A., Pszczoła, J., Lisowska, A., Knapp, M., Sobkowicz, B., Kamiński, K. A., & Ptaszyńska‐Kopczyńska, K. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221087846 · Cited by 24
Wronski, S. L., Mordin, M., Kelley, K., Anguiano, R. H., Classi, P. M., Shen, E., & Manaker, S. (2019) · Lung · doi:10.1007/s00408-019-00289-2 · Cited by 24
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Hoeper, M. M., Boucly, A., & Sitbon, O. (2018) · European Respiratory Journal · doi:10.1183/13993003.00629-2018 · Cited by 24
Self-citationHeresi, G. A., & Rao, Y. (2020) · Lung · doi:10.1007/s00408-020-00402-w · Cited by 23
“Our results are consistent with those of recently published registry data from Europe [22, 23], suggesting that achieving these goals as early as 3–4 months after the start of therapy is associated long-lasting benefits.”
ResultWilson, M. A., Keeley, J. H., Kingman, M. S., Wang, J., & Rogers, F. (2020) · Pulmonary Circulation · doi:10.1177/2045894020950186 · Cited by 23
“2%, respectively.(13) Similarly, when 1017 PAH patients were stratified into risk categories using FPHR, there were significant differences in the rates of transplant-free survival for the different risk groups, with a greater number of lowrisk criteria at baseline associated with better outcomes.”
BackgroundMin, J., Badesch, D. B., Chakinala, M. M., Elwing, J., Frantz, R. P., Horn, E. M., Klinger, J. R., Lammi, M. R., Mazimba, S., Sager, J. S., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202010-3967le · Cited by 23
“COMPERA=Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; HRQoL=health-related quality of life; REVEAL=Registry to Evaluate Early and Long-Term PAH Disease Management.”
InfluentialMiotti, C., Papa, S., Manzi, G., Scoccia, G., Luongo, F., Toto, F., Malerba, C., Cedrone, N., Sciomer, S., Ciciarello, F., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040619 · Cited by 23
“International guidelines recommend optimization of treatment based on regular risk assessments to achieve or maintain a low-risk status [2] as defined by risk scores derived from different registries: Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) [3], Comparative, Prospective Registry of New…”
MethodSelf-citationArvidsson, M., Ahmed, A., Säleby, J., Hesselstrand, R., & Rådegran, G. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12041 · Cited by 23
Zambrano, B. A., McLean, N., Zhao, X., Tan, J.-L., Zhong, L., Figueroa, C. A., Lee, L. C., & Baek, S. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.611149 · Cited by 22
Medical Management of Pulmonary Arterial Hypertension: Current Approaches and Investigational Drugs
Jin, Q., Chen, D., Zhang, X., Zhang, F., Zhong, D., Lin, D., Guan, L., Pan, W., Zhou, D., & Ge, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061579 · Cited by 22
“At present, the recommended risk stratification assessment scales for PAH mainly include: the French Pulmonary Hypertension Network Risk Assessment Equation [16], REVEAL risk score [17], Pulmonary Hypertension Connection Equation [18], 2015 ESC/ERS PH guideline risk assessment model [1], COMPERA ESC/ERS abbreviated ri…”
MethodPulmonary hypertension – the latest updates for physicians
Virsinskaite, R., Karia, N., Kotecha, T., Schreiber, B. E., Coghlan, G., & Knight, D. S. (2023) · Clinical Medicine · doi:10.7861/clinmed.2023-23.5.cardio4 · Cited by 22
Li, Q., Zhang, Y., Cui, X., Lu, W., Ji, Q., & Zhang, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14752 · Cited by 22
Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects
Sharma, M., Paudyal, V., Syed, S., Thapa, R., Kassam, N., & Surani, S. (2025) · Life · doi:10.3390/life15030430 · Cited by 22
Yanaka, K., Guillien, A., Soumagne, T., Bénet, J., Piliero, N., Picard, F., Pison, C. M., Sitbon, O., Bouvaist, H., & Degano, B. (2020) · European Respiratory Journal · doi:10.1183/13993003.02418-2019 · Cited by 22
Risk assessment in severe pulmonary hypertension due to interstitial lung disease
Yogeswaran, A., Tello, K., Faber, M., Sommer, N., Kuhnert, S., Seeger, W., Grimminger, F., Ghofrani, H. A., Richter, M. J., & Gall, H. J. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.06.014 · Cited by 22
Self-citationBrugger, N., Lichtblau, M., Maeder, M. T., Müller, H., Pellaton, C., Yerly, P., & Swiss Society For Pulmonary Hypertension Ssph (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.20486 · Cited by 23
Berghausen, E. M., Janssen, W., Vantler, M., Gnatzy-Feik, L., Krause, M., Behringer, A., Joseph, C. G., Zierden, M., ten Freyhaus, H., Klinke, A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci136939 · Cited by 22
Self-citationHumbert, M. J. C., & Weatherald, J. C. (2018) · European Respiratory Journal · doi:10.1183/13993003.00738-2018 · Cited by 22
Metadata
- Authors
- Hoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., Distler, O., Opitz, C., Gibbs, J. S. R., Delcroix, M., Ghofrani, H. A., Huscher, D., Pittrow, D., Rosenkranz, S., & Grünig, E.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- University of Cologne (DE)
- University Hospital Heidelberg (DE)
- Heinrich Heine University Düsseldorf (DE)
- Sapienza University of Rome (IT)
- University Hospital Zurich (CH)
- DRK Kliniken Berlin (DE)
- Imperial College London (GB)
- Universitair Ziekenhuis Leuven (BE)
- Justus-Liebig-Universität Gießen (DE)
- Technische Universität Dresden (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-08
- Volume
- 50
- Issue
- 2
- Pages
- 1700740
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2743897368
- Cited by
- 660
- References
- 21
- Citations by year
- 2026: 21 · 2025: 52 · 2024: 74 · 2023: 84 · 2022: 101 · 2021: 111 · 2020: 92 · 2019: 63 · 2018: 53 · 2017: 8
- FWCI
- 48.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- GlaxoSmithKline
- German Centre of Lung Research
- Bayer
- Actelion Pharmaceuticals
- Deutsche Forschungsgemeinschaft (HO 1599/2-1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- pulmonary arterial hypertension, mortality prediction, risk stratification, one-year mortality, functional class, 6-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, mixed venous oxygen saturation
- MeSH terms
- Walk Test, Adult, Aged, Aged, 80 and over, Europe, Female, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Prospective Studies, Registries, Severity of Illness Index, Practice Guidelines as Topic, Risk Assessment, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.